Hepatitis C in Patients with Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes

Zobair M. Younossi, Maria Stepanova, Tarik Asselah, Graham Foster, Keyur Patel, Norbert Bräu, Mark Swain, Tram Tran, Rafael Esteban, Massimo Colombo, Stephen Pianko, Linda Henry, Marc Bourliere

Research output: Contribution to journalArticleResearchpeer-review

15 Citations (Scopus)

Abstract

© The Author(s) 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. Background While the necessity of treatment of hepatitis C virus (HCV)-infected patients with advanced liver disease is widely accepted, the benefit of treating patients without significant liver disease is less well established. Our aim was to assess the effect of treating HCV in patients with no or minimal fibrosis (Metavir stage F0-F1) on patient-reported outcomes (PROs). Methods HCV-infected patients with F0-F1 from 16 clinical trials were included. PROs were collected before, during, and after treatment. Results A total of 1548 HCV-infected patients with F0-F1 were included (mean age 46 years, 43% male, 81% treatment-naive). Patients were treated with interferon (IFN) + sofosbuvir (SOF) + ribavirin (RBV) (n = 91) or SOF + RBV with or without ledipasvir (n = 479) or IFN- and RBV-free regimens with SOF + ledipasvir or SOF + velpatasvir or SOF + velpatasvir + voxilaprevir (n = 978). By the end of treatment, patients receiving IFN-containing regimens experienced significant decreases in most PRO domains (-4.5 to -28.7 on a 0-100 scale), while subjects treated with IFN-free RBV-containing regimens had a modest impairment (-2.3 to -8.9) (P ≤.01). In contrast, treatment with regimens without IFN and RBV led to PRO improvements (+1.2 to +10.9). Regardless of the regimen, sustained virologic responses (SVRs) at 12 and 24 weeks were universally associated with PRO improvements (+2.1 to +14.7, P <.0001. Conclusions HCV-infected subjects with no or minimal fibrosis treated with IFN- and RBV-free regimens experienced on-treatment and post-SVR PRO improvements.
Original languageEnglish
Pages (from-to)1742-1750
JournalClinical Infectious Diseases
Volume66
Issue number11
DOIs
Publication statusPublished - 17 May 2018

Keywords

  • direct-acting antivirals
  • fatigue
  • healthy liver
  • vitality
  • work productivity

Fingerprint Dive into the research topics of 'Hepatitis C in Patients with Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes'. Together they form a unique fingerprint.

Cite this